drugset / Trial / NCT01407094

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094

Phase 2 Completed 296 enrolled University of Texas Southwestern Medical Center
RandomizedSequentialQuadruple-blindOther

Summary

This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches. The study is designed to identify moderators and mediators of treatment response for depression in order to specify a biosignature of treatment response for depression. Evaluation of the usefulness of these markers in a carefully conducted clinical trial comparing an antidepressant to placebo will assist in developing a Depression Treatment Response Index (DTRI) to help clinicians match treatments to patients with MDD, resulting in timely selection of treatments best suited for individual patients and thus approaching personalized treatment. The resulting index provides a truly novel means of synthesizing the contribution of key clinical and biological parameters in an easy to use tool for clinical care.

Timeline

Start
2011-07-29
Primary completion
2016-04
Completion
2016-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 150 mg
Comparator Bupropion Small molecule 450 mg
Comparator Sertraline Small molecule 50 mg
Comparator Sertraline Small molecule 200 mg

Indications